A 4-week, Phase III, Multicenter, Double-masked, Vehicle-controlled Clinical Study to Evaluate Safety and Efficacy of Oxervate® (Cenegermin) 20 mcg/mL Ophthalmic Solution Versus Vehicle, in Patients With Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Cenegermin (Primary)
- Indications Dry eyes; Sjogren's syndrome
- Focus Registrational; Therapeutic Use
- Acronyms NGF0121
- Sponsors Dompe Farmaceutici
- 06 Sep 2023 This trial has been completed in Italy According to European Clinical Trials Database record
- 01 Jun 2023 Planned End Date changed from 1 May 2023 to 31 Jul 2023.
- 24 Oct 2022 Planned End Date changed from 1 Jan 2023 to 1 May 2023.